➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Dow
Boehringer Ingelheim
Johnson and Johnson
Moodys
Express Scripts

Last Updated: October 24, 2021

DrugPatentWatch Database Preview

Vale Company Profile


Email this page to a colleague

« Back to Dashboard

Summary for Vale
International Patents:62
US Patents:8
Tradenames:73
Ingredients:56
NDAs:93
Patent Litigation for Vale: See patent lawsuits for Vale

Drugs and US Patents for Vale

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Valeant Pharms Intl LACRISERT hydroxypropyl cellulose INSERT;OPHTHALMIC 018771-001 Approved Prior to Jan 1, 1982 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial
Valeant Pharm Intl OXSORALEN methoxsalen LOTION;TOPICAL 009048-002 Approved Prior to Jan 1, 1982 DISCN Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial
Valeant Pharm Intl TETRACYCLINE HYDROCHLORIDE tetracycline hydrochloride CAPSULE;ORAL 060471-002 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Free Forever Trial ⤷  Free Forever Trial
Valeant Pharms Intl GIAZO balsalazide disodium TABLET;ORAL 022205-001 Feb 3, 2012 DISCN Yes No 8,497,256 ⤷  Free Forever Trial ⤷  Free Forever Trial
Valeant Pharms MINITRAN nitroglycerin FILM, EXTENDED RELEASE;TRANSDERMAL 089774-001 Aug 30, 1996 DISCN No No ⤷  Free Forever Trial ⤷  Free Forever Trial
Valeant BONTRIL PDM phendimetrazine tartrate TABLET;ORAL 085272-001 Approved Prior to Jan 1, 1982 AA RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Vale

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Valeant Pharms Intl APRISO mesalamine CAPSULE, EXTENDED RELEASE;ORAL 022301-001 Oct 31, 2008 8,337,886 ⤷  Free Forever Trial
Valeant Luxembourg VISUDYNE verteporfin INJECTABLE;INJECTION 021119-001 Apr 12, 2000 5,283,255 ⤷  Free Forever Trial
Valeant Pharms Llc MACUGEN pegaptanib sodium INJECTABLE;INTRAVITREAL 021756-001 Dec 17, 2004 5,932,462 ⤷  Free Forever Trial
Valeant Pharms ULTRAM ER tramadol hydrochloride TABLET, EXTENDED RELEASE;ORAL 021692-003 Sep 8, 2005 6,254,887 ⤷  Free Forever Trial
Valeant Bermuda RETIN-A tretinoin CREAM;TOPICAL 017522-001 Approved Prior to Jan 1, 1982 3,906,108 ⤷  Free Forever Trial
Valeant Pharms Llc TIMOPTIC-XE timolol maleate SOLUTION, GEL FORMING/DROPS;OPHTHALMIC 020330-002 Nov 4, 1993 4,195,085 ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for VALE drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Gel 0.1% ➤ Subscribe 2010-07-08
➤ Subscribe Capsules 75 mg ➤ Subscribe 2011-06-06
➤ Subscribe Extended-release Tablets 200 mg ➤ Subscribe 2007-03-28
➤ Subscribe Extended-release Capsules 0.375 g ➤ Subscribe 2012-04-03
➤ Subscribe Cream 0.5% ➤ Subscribe 2011-07-29
➤ Subscribe Gel 0.04% ➤ Subscribe 2010-12-20
➤ Subscribe Extended-release Tablets 100 mg ➤ Subscribe 2007-01-08
➤ Subscribe Extended-release Tablets 300 mg ➤ Subscribe 2007-09-25
➤ Subscribe Tablets 1.1 g ➤ Subscribe 2013-11-05

Supplementary Protection Certificates for Vale Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1304992 132013902214376 Italy ⤷  Free Forever Trial PRODUCT NAME: CLINDAMICINA FOSFATO E TRETINOINA(ACNATAC); AUTHORISATION NUMBER(S) AND DATE(S): PA1332/043/001, 20130322;042056010/M - 022/M, 20130718
0957929 20/2006 Austria ⤷  Free Forever Trial PRODUCT NAME: PEGAPTANIB UND SALZE DAVON; REGISTRATION NO/DATE: EU/1/05/325/001 20060131
0637297 C300054 Netherlands ⤷  Free Forever Trial PRODUCT NAME: BEXAROTENE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AAN- VAARDBAAR ZOUT OF IN DE VORM VAN EEN ESTER MET EEN HYDROXYVER- BINDING MET DE FORMULE R9OH, WAARIN R9 EEN; NAT. REGISTRATION NO/DATE: EU/1/01/178/001 20010329; FIRST REGISTRATION: EU/1/01/178/001 20010329
1304992 PA2013025 Lithuania ⤷  Free Forever Trial PRODUCT NAME: CLINFAMYCINUM + TRETINOINUM; REGISTRATION NO/DATE: LT/1/13/3279/001, 2013 04 26 LT/1/13/3279/002, 2013 04 26 PA1332/043/001 20130323
0509752 49/1999 Austria ⤷  Free Forever Trial PRODUCT NAME: DORZOLAMID ODER EIN OPHTHALMOLOGISCH ANNEHMBARES SALZ DAVON, VORZUGSWEISE DORZOLAMIDHYDROCHLORID, UND TIMOLOL ODER EIN OPHTHALMOLOGISCH ANNEHMBARES SALZ DAVON, VORZUGSWEISE TIMOLOLMALEAT; NAT. REGISTRATION NO/DATE: 1-22701, 1-22702 19980828; FIRST REGISTRATION: DK 9794 19980306
0509752 C990041 Netherlands ⤷  Free Forever Trial PRODUCT NAME: DORZOLAMIDE, DESGEWENST IN DE VORM VAN EEN OFTALMOLOGISCH AAN- VAARDBAAR ZOUT, EN TIMOLOL, DESGEWENST IN DE VORM VAN EEN OFTAL -MOLOGISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER DORZOLLAMIDEHY- DROCHLORIDE EN TIMOLOLMALEAAT, EEN EN ANDER ZODANIG DAT 0,05; NATL REGISTRATION NO/DATE: VG 22871 19980805; FIRST REGISTRATION: DK 19045 19980306
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Boehringer Ingelheim
McKinsey
Harvard Business School
Baxter
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.